Viewing Study NCT03298451


Ignite Creation Date: 2025-12-24 @ 11:55 PM
Ignite Modification Date: 2026-01-04 @ 5:45 AM
Study NCT ID: NCT03298451
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-15
First Post: 2017-09-19
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Sponsor: AstraZeneca
Organization: